Q-Sphera allows drug compounds to be released into the body in a “highly controlled manner” over a prolonged period of time; potentially from a few days to up to six months.
Under the collaboration agreement, the unnamed partner will conduct a feasibility program using the Q-Sphera technology. No financial terms have been disclosed.
A study of Midatech’s MTD201 acromegaly treatment earlier this year provided a major validation of the platform, with results showing two things: that MTD201 was possibly a better treatment than rival one developed by Novartis but also that Q-Sphera works.
“We are delighted to announce this partnership with a leading global pharmaceutical corporation,” said chief executive Craig Cook.
“This marks another important step in the development of our impressive Q-Sphera technology, after the positive clinical 'proof of concept' first-in-human study earlier this year in carcinoid cancer and acromegaly.”
He added: “Together with partnerships such as the one being announced we are focused on increasing our traction in the sustained delivery market, where we hope to establish Q-Sphera as the leading platform.”